| Title |
|
|
|
The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia
|
|
| Author |
|
|
|
|
|
| Abstract |
|
|
|
| Low average specificity levels of 48% for clinical diagnosis of possible Alzheimer's disease (AD) reflect the overlap of clinical profiles between AD and non-AD dementias. Should diagnostic errors occur, they most likely involve one of the other primary dementias, mixed pathologies that include a vascular component, or uncertainties that are associated with early diagnosis. Vascular dementia (VaD) is overdiagnosed when a routine brain MRI or CT scan is used in the context of standard clinical diagnostic criteria, meanwhile denying significant neurodegenerative co-pathology. A promising approach for increasing diagnostic accuracy is the use of biochemical markers (biomarkers) that are present in the cerebrospinal fluid (CSF). The CSF biomarkers ß-amyloid protein of 42 amino acids (Aß142), total tau protein (T-tau), and tau phosphorylated at threonine 181 (P-tau181P) are well validated. A combined analysis of these biomarkers is of help to discriminate AD from non-AD dementias (including VaD), reaching sensitivity and specificity levels that exceed 80%. Moreover, the added value of CSF biomarkers could lie within those cases in which the clinical diagnostic work-up is not able to discriminate between AD or a non-AD dementia. In case of doubt between VaD or mixed ADVaD pathology in dementia patients, the determination of CSF Aß142, T-tau and P-tau181P levels is of help to confirm or exclude the AD component in the pathophysiology of the dementia syndrome. | |
|
| Language |
|
|
|
English
|
|
| Source (journal) |
|
|
|
Journal of the neurological sciences. - Amsterdam |
|
| Publication |
|
|
|
Amsterdam : 2012
|
|
| ISSN |
|
|
|
0022-510X
|
|
| Volume/pages |
|
|
|
322:1-2(2012), p. 197-199
|
|
| ISI |
|
|
|
000310819500041
|
|
| Full text (Publisher's DOI) |
|
|
| |
|
| Full text (publisher's version - intranet only) |
|
|
| |
|